Sanofi has added to its vaccine pipeline with an agreement to acquire Austria's Origimm Biotechnology and its vaccine-based immunotherapy for people with acne.
The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho